ReviewFrontiers in microbiology2022
COVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Fosmanogepix: A comprehensive review of its origin, mechanism, antifungal efficacy, and resistance (Review).Biomedical reports · 2026Review
- Antifungal Susceptibility Patterns in Respiratory Tract Candidiasis and Risk Factors Among HIV-Infected Adults in South West Cameroon.Antibiotics (Basel, Switzerland) · 2026Article
- Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Species distribution and antifungal susceptibility of Candida isolates from sterile body sites: a 14-year retrospective study at a tertiary care hospital in China (2010-2023).BMC microbiology · 2026Observational
- Assessing antifungal stewardship competency among pharmacy students: key findings and implications for clinical practice.Frontiers in public health · 2026Article
- Review
- Fungal Pulmonary Coinfections in COVID-19: Microbiological Assessment, Inflammatory Profiles, and Clinical Outcomes.Biomedicines · 2025Article
- Epidemiology of mucormycosis in COVID-19 patients in northwest Iran:Current medical mycology · 2025Article
- Synthesis, In Silico Study, and In Vitro Antifungal Activity of New 5-(1,3-Diphenyl-1International journal of molecular sciences · 2024Article
- The Impact of Antifungal Stewardship on Clinical and Performance Measures: A Global Systematic Review.Tropical medicine and infectious disease · 2023Review
- Unveiling the mechanism of action of acylated temporin L analogues against multidrug-resistantJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Discovery and development of novel substituted monohydrazides as potent antifungal agents.RSC medicinal chemistry · 2023Article
- Coinfections and Superinfections Associated with COVID-19 in Colombia: A Narrative Review.Medicina (Kaunas, Lithuania) · 2023Review
- Fungal Infections Identified with Multiplex PCR in Severe COVID-19 Patients during Six Pandemic Waves.Medicina (Kaunas, Lithuania) · 2023Article
- Controlling antifungal activity with light: Optical regulation of fungal ergosterol biosynthetic pathway with photo-responsive CYP51 inhibitors.Acta pharmaceutica Sinica. B · 2023Article
- Development of a Novel Method for the Clinical Visualization and Rapid Identification of Multidrug-Resistant Candida auris.Microbiology spectrum · 2023Article
- Post-COVID-19 Fungal Infection in the Aged Population.Vaccines · 2023Review
- COVID-19 in pulmonary critically ill patients: metagenomic identification of fungi and characterization of pathogenic microorganisms.Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary fungal infections may complicate the clinical course of patients affected by viral respiratory diseases, especially those admitted to intensive care unit. Hospitalized COVID-19 patients are at increased risk of fungal co-infections exacerbating the prognosis of disease due to misdiagnosis that often result in treatment failure and high mortality rate. COVID-19-associated fungal infections caused by predominantly
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.